遗传变异对普雷加巴林药理动力学和安全性的影响
Sofía Calleja1, Andrea Rodríguez-López1, Dolores Ochoa1
1Clinical Pharmacology Department, Hospital Universitario de La Princesa, Faculty of Medicine, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria La Princesa (IIS-Princesa), 28006 Madrid, Spain.
遗传变异,如NAT2缓慢的乙化剂,可能会略微影响普雷加巴林 (普雷加巴林) 药理动力学,但性差异的暴露对预测药物不良反应更为关键,而不是遗传学.
科学领域:
- 药物基因组学 药物基因组学
- 临床药理学 临床药理学
背景情况:
- 普雷加巴林是神经病痛和焦虑症的关键治疗方法.
- 药物载体和代谢酶的遗传变异可以影响药物的有效性和安全性.
- 了解这些遗传因素对于优化普雷加巴林治疗至关重要.
研究的目的:
- 研究基因变异对普雷加巴林药理动力学和安全性的影响.
- 探索特定基因变异在药物吸收,分布和新陈代谢中的作用.
- 为了确定潜在的药物遗传生物标志物用于普雷加巴林治疗.
主要方法:
- 进行了与24名健康志愿者接受普雷加巴林 (300毫克口服) 的生物等效试验.
- 在31个候选基因中,对23名受试者进行了114个变异的基因定型.
- 分析了基因变异,普雷加巴林暴露 (AUC∞,Cmax) 和药物不良反应 (ADR) 之间的关联.
主要成果:
- 女性的AUC∞和Cmax显著高于男性,尽管剂量/体重调整后的暴露程度相似.
- 与中间 (IAs) 和正常 (NAs) 乙化剂相比,NAT2缓慢乙化剂 (SAs) 的暴露增加,半衰期延长 (t1/2).
- 无论是NAT2表型还是其他遗传变异都没有预测ADR;性别和相关暴露差异是主要预测因素.
结论:
- NAT2基因型可能在普雷加巴林代谢中起到较小的作用,但其临床相关性似乎有限.
- 药物遗传生物标志物目前在指导普雷加巴林药物治疗方面发挥的作用有限.
- 在预测药物不良反应方面,基于性别的普雷加巴林暴露差异比遗传变异更为重要.
更多相关视频
07:01Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
11:35Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay EMSA and DNA-affinity Precipitation Assay DAPA
Published on: August 21, 2016
相关概念视频
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
Factors Affecting Protein-Drug Binding: Patient-Related Factors
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
Nonlinear Pharmacokinetics: Role of Transporters
Polymorphisms occurring in drug transporters can alter...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
